Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cambridge Cognition HoldingsLSE:COG 47 Earnings Yield (Joel Greenblatt) % is -9.80% as of Dec. 2025. GuruFocus rates LSE:COG with a GF Score™ of 47/100 and a GF Value™ of £0.33 (Fairly Valued). The stock has 5 warning signs investors should review. Among 681 Healthcare Providers & Services companies, Cambridge Cognition Holdings ranks worse than 80.62% on this metric.
Cambridge Cognition Holdings's Enterprise Value for the quarter that ended in Dec. 2025 was £12.78 Mil.
Cambridge Cognition Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was £-1.25 Mil. Cambridge Cognition Holdings's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was -9.80%.
The historical rank and industry rank for Cambridge Cognition Holdings's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
LSE:COG'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -85.53 Med: -6.75 Max: 1.03
Current: -7.14
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Cambridge Cognition Holdings was 1.03%. The lowest was -85.53%. And the median was -6.75%.
LSE:COG's Earnings Yield (Joel Greenblatt) % is ranked worse than 80.62% of 681
companies
in the Healthcare Providers & Services industry
Industry Median: 3.52
vs LSE:COG: -7.14
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Cambridge Cognition Holdings's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Cambridge Cognition Holdings Earnings Yield (Joel Greenblatt) % Related Terms
Cambridge Cognition Holdings Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Cambridge Cognition Holdings's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Cambridge Cognition Holdings's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cambridge Cognition Holdings Earnings Yield (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cambridge Cognition Holdings's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Cambridge Cognition Holdings's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Cambridge Cognition Holdingss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of -9.80% mean?
Cambridge Cognition Holdings (LSE:COG) has a Earnings Yield (Joel Greenblatt) % of -9.80% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Cambridge Cognition Holdings and its competitors. According to the industry distribution chart, Cambridge Cognition Holdings ranks #549 out of 681 companies in the Healthcare Providers & Services industry, placing it in the top 80.6%.
Is Cambridge Cognition Holdings' Earnings Yield (Joel Greenblatt) % too high?
Cambridge Cognition Holdings' current Earnings Yield (Joel Greenblatt) % is -9.80%. Based on the distribution chart, Cambridge Cognition Holdings ranks #549 out of 681 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cambridge Cognition Holdings has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cambridge Cognition Holdings' Earnings Yield (Joel Greenblatt) % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Cambridge Cognition Holdings ranks #549 out of 681 companies for Earnings Yield (Joel Greenblatt) %. This places Cambridge Cognition Holdings in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median Earnings Yield (Joel Greenblatt) % among Healthcare Providers & Services companies is 3.52, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Cambridge Cognition Holdings and its competitors. For the Healthcare Providers & Services industry, the median Earnings Yield (Joel Greenblatt) % is 3.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cambridge Cognition Holdings's current Earnings Yield (Joel Greenblatt) % is -9.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Cognition Holdings stock overvalued right now?
Based on GuruFocus' analysis, Cambridge Cognition Holdings (LSE:COG) is currently considered Fairly Valued. The stock's GF Value™ is £0.33, compared to a current price of £0.33 — trading right at its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -9.80%. Cambridge Cognition Holdings' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Cambridge Cognition Holdings (LSE:COG), the current Earnings Yield (Joel Greenblatt) % is -9.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cambridge Cognition Holdings (LSE:COG) Overvalued in 2026?
Based on GuruFocus' analysis, Cambridge Cognition Holdings stock appears to be undervalued.
The current stock price of £0.33 is trading 0% below its estimated GF Value™ of £0.33.
GuruFocus considers Cambridge Cognition Holdings to be Fairly Valued.
Key valuation signals for LSE:COG:
Earnings Yield (Joel Greenblatt) %: -9.80%
GF Value™: £0.33 vs. price of £0.33 (0% below fair value)
No single metric tells the full story. See the LSE:COG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cambridge Cognition Holdings PLC is a neuroscience digital health company specializing in the measurement of clinical outcomes in neurological disorders. It develops and commercialises neuroscience technologies to assess cognitive function for sale across the world. The company's products include CANTAB web-based assessments, Electronic questionnaires and scales (eCOA), NeuroVocalix Winterlight, a voice analysis tool to assess cognitive changes, high-frequency testing kits, and Clinpal, among others. Its operating segments are: Clinical studies, which generate maximum revenue, Academic research, Professional Healthcare, and Consumer Health & Wellness. Geographically, the company generates maximum revenue from the USA, and the rest from the UK, the European Union, and the Rest of the world.
47GF Score
Get the complete analysis for LSE:COG
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:COG has been successfully added to your 
